MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.

摘要: Abstract Background Currently, the main treatment for non-small cell lung cancer (NSCLC) is surgery and chemotherapy. Although major progress has been made in targeted immunotherapy, survival rates this disease are still low associated with resistance to Previous studies have shown that histone acetylation microRNAs (miRNAs) might play an important role chemotherapy resistance. The aim of study was identify candidate miRNAs related cisplatin (DDP) adenocarcinoma. Methods We used 5-aza-2′-deoxycytidine trichostatin A reverse drug A549/DDP cells vitro, miRNA expression profiling performed by microarrays miRNAs. In addition, we investigated correlations between miR-320a clinical characteristics through data collected from Gene Expression Omnibus (GEO) microarrays, Cancer Genome Atlas (TCGA) determine Furthermore, biological function miR-320a. TargetScanHuman, PicTar2005 miRanda v5.1. were predict target genes miR-320a; then, these suggested enrichment GO categories items KEGG analyses. Results Treatment 5-Aza-dc significantly inhibited cellular proliferation, increased apoptosis compared untreated cells. TSA did not MiR-320a up-regulated during reversal adenocarcinoma groups had a lower level than control groups. For bioinformatics analyses, found some involved cycle progression, tumor MAPK signaling pathway, ErbB pathway. promising highly enriched various pathways cancer. Conclusions current confirmed revering results analyses may present new method investigating pathogenesis